OnKure Therapeutics, Inc. (OKUR)

CIK 0001637715 · Healthcare · Biotechnology

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest Q2-2026 8-K (2026-08-04) · 99.1
Q1-2026 8-K (2026-05-05) · 99.1
Latest FY-2025 8-K (2026-03-12) · 99.1
Q3-2025 8-K (2025-11-06) · 99.1
Q2-2025 8-K (2025-08-12) · 99.1
Q1-2025 8-K (2025-05-06) · 99.1
FY-2024 8-K (2025-03-10) · 99.1
Q3-2024 —
Q2-2024 8-K (2024-08-13) · 99.1
Q1-2024 8-K (2024-05-07) · 99.1
FY-2023
FY-2023 8-K (2024-03-28) · 99.1
Q3-2023 8-K (2023-11-13) · 99.1

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Cover Page
Document and Entity Information
Statements
Consolidated Balance Sheets
Consolidated Balance Sheets (P)
Consolidated Statements of Operations and Comprehensive Loss
Condensed Consolidated Statements of Changes In Convertible Preferred Stock and Stockholders' Equity (unaudited)
—
Consolidated Statements of Changes In Stockholders' Equity
Consolidated Statements of Cash Flows
Consolidated Statements of Changes In Stockholders' Equity (P)
—
Notes
Accounts Payable and Accrued Expenses and Other Current Liabilities
—
Accrued Expenses
Accrued Expenses and Other Current Liabilities
—
Commitments and Contingencies
Convertible Promissory Notes
—
Cybersecurity
—
Equity
Fair Value Measurements
Financial Impact of Suspension of Mavodelpar Development Activities
—
Income Taxes
Insider Trading Arrangements
Insider Trading Policies and Procedures
—
Leases
License Agreement
Marketable Debt Securities
Merger Agreement and Concurrent Financing
Net Loss Per Share
Organization and Business
Pay Vs Performance Disclosure
Prepaid Expenses and Other Current Assets
—
Property and Equipment, Net
Segment
Share-based Compensation
Stock-based Compensation
Stockholders' Equity
—
Subsequent Events
Summary of Significant Accounting Policies